Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or II (Stage IIB N0, M0) non-small cell lung cancer (NSCLC).
The primary study hypothesis is SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared to SBRT plus placebo (normal saline solution).
As of protocol amendment 8, the study was stopped due to an interim analysis that did not support the study primary and key secondary endpoints.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
448 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Toll Free Number
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal